{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-012238","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.983717+00:00","generated_at":"2026-05-15T23:30:40.912685+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Pacira BioSciences reports Q4 2025 revenue of $196.9M, up 5%, and full-year 2026 guidance","bullets":["Q4 2025 total revenue $196.9M (5% increase vs Q4 2024); EXPAREL sales $155.8M (+5%)","Full-year 2025 revenue $726.4M; GAAP net income $7.0M vs net loss of $99.6M in 2024","Repurchased 5.9M shares for $150.0M in 2025; $150M remaining authorization through Dec 2026","2026 guidance: EXPAREL net sales $600-620M, total revenue $745-770M, gross margin 77-79%","Strategic partnership with LG Chem for EXPAREL in select Asian-Pacific markets; Samit Hirawat appointed to board"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-012238","json":"https://secwatch.observer/filing/0001628280-26-012238.json","markdown":"https://secwatch.observer/filing/0001628280-26-012238.md","text":"https://secwatch.observer/filing/0001628280-26-012238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/0001628280-26-012238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/pcrx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T23:30:40.912685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}